Sacramento, California -- Biotechnology company SynGen has received $1.56 million in venture capital equity and debt, according to an SEC regulatory filing.
SynGen is commercializing technologies that "isolate capture stem and progenitor cells from peripheral and umbilical cord blood, bone marrow and adipose tissue."
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of three investors participated in the offering
CEO William Gerber has been with the company since May 2014.